The Sensor Relies on a Polyclonal DNA Aptamer Library Produced Through Nine Rounds of FluMag-SELEX

The sensor relies on a polyclonal DNA aptamer library produced through nine rounds of FluMag-SELEX, and it delivers label-free detection in complex biological matrices, according to the study posted at Research Square ahead of peer review.

Why should capital markets care about a bench-top biosensor? Because soluble α-Klotho is a notoriously difficult biomarker. The full-length protein is cleaved into a soluble form that circulates at low concentrations, and existing detection routes lean on ELISA kits with known reproducibility problems.

The study's own reference list cites work by Yamazaki and colleagues establishing a sandwich ELISA for soluble α-Klotho and later reference-value studies in healthy adults aged 18 to 85, which shows how fragmented the measurement standard has been. A faster, label-free quantification method would be the enabling layer for any diagnostics company betting on Klotho as a commercial biomarker for aging, diabetes and kidney-related indications.

Aptamer pool achieves high specificity for α-Klotho

  • A nine-round FluMag-SELEX process produced a polyclonal aptamer pool with high affinity and specificity for α-Klotho and its KL1 domain, per the preprint.
  • The aptamer-linked fluorescence assay (ALFA) distinguished α-Klotho from β-Klotho and homologous proteins in human serum — the specificity hurdle that kills most biomarker platforms.
  • Integration into a gFET achieved label-free, fast quantification, positioning the platform in the same category as graphene-biosensor players competing for point-of-care diagnostics spending.

Nine rounds, 6 × 10¹³ candidates

This is the math behind the selection. The team started with a commercial oligonucleotide library from TriLink BioTechnologies containing roughly 6 × 10¹³ individual ssDNA molecules — a 100 pmol input — each carrying a central 40-nucleotide random region flanked by 23-nucleotide primer binding sites. That random region offers far larger theoretical sequence diversity, though the researchers state plainly that the actual number of distinct sequences was not experimentally determined.

The target was recombinant human α-Klotho (MedChemExpress, Cat. No. HY-P700011), expressed in CHO cells and spanning the extracellular domain E34–S981 with both KL1 and KL2 domains. The protein ran at approximately 110–130 kDa under reducing SDS-PAGE with purity of at least 95%, and the manufacturer confirmed biological activity through NIH-3T3 cell proliferation (EC40 below 1 µg/mL) and FGF23 binding (EC50 of 0.64–1.25 µg/mL).

KL1 matters commercially because it mediates most of Klotho’s signaling activity, including modulation of fibroblast growth factor pathways — the mechanism that ties the protein to aging, diabetes and Alzheimer’s disease research.

Selection pressure escalated across the rounds. Input dropped from 10 pmol in rounds 2 and 3 to 1 pmol in rounds 4 through 6, then 0.1 pmol for rounds 7 through 9, with increasing BSA and tRNA blocking and, from round 5, BSA in the wash buffer.

Enrichment was tracked by qPCR with absolute quantification against a calibration curve spanning 0.005 to 5 pg/µL, and binding assays on Cy5-labeled libraries from rounds 3, 5, 7 and 9 confirmed the pool was converging on Klotho-loaded beads rather than the unloaded controls.

Where the money sits

But the platform economics tell the more interesting story. The aptamer route attacks the cost structure of antibody-based diagnostics. The study’s bibliography cites Chen and Yang’s work on replacing antibodies with aptamers in lateral flow immunoassays, published in Biosensors & Bioelectronics, and earlier head-to-head comparisons of antibody versus aptamer receptors on impedance biosensors.

Aptamers are produced chemically, batch-to-batch consistent, and can be regenerated — three levers that directly affect cost of goods in diagnostics manufacturing.

The gFET integration is the part with the clearest addressable market. Graphene field-effect transistors enable label-free electrical readout, which strips out fluorescent tags, wash steps and plate readers. That compresses time-to-result and pushes testing toward point-of-care settings.

The graphene sensor supply chain — CVD graphene wafers, functionalized chips, readout electronics — sits largely with specialty materials suppliers rather than semiconductor giants, though Thermo Fisher Scientific (NYSE: TMO) appears in this workflow twice: its Dynabeads M-280 tosyl-activated beads carried the Klotho immobilization, and the work was performed at institutions in Austria and Germany, not at a US hub.

Investors tracking this space should note the competitive framing. ELISA's weaknesses — multi-hour protocols, plate-based throughput, variability across kit lots — are precisely the gaps a gFET reads out in near real time. The counterweight: this is a preprint.

It has not cleared peer review, the apparent dissociation constant is reported as a Kd,app for a heterogeneous polyclonal pool rather than for individual aptamer sequences, and no commercial partner or licensing arrangement is named in the material.

The specificity problem, solved or not

The team’s own data addresses the question that sinks most Klotho assays: cross-reactivity. The ALFA format selectively detected α-Klotho in human serum while distinguishing it from β-Klotho and homologous proteins, the abstract states. Fluorescence microscopy on round-9 libraries bound to Klotho-loaded versus unloaded beads provided visual confirmation alongside the microplate fluorescence readings at 670 nm excitation of 635 nm.

Who gains if this validates? Diagnostics developers holding Klotho biomarker programs gain a measurement tool that could standardize serum reference ranges — a prerequisite for any clinical trial using Klotho as an endpoint. ELISA kit manufacturers lose pricing power on the same niche. Contract research organizations running aging and nephrology studies gain a faster readout.

And the patients-with-capital demographic driving the longevity economy — a market segment that has pushed spending on biological-age testing into the billions — gains a candidate biomarker that correlates, per epidemiological work cited in the study, with all-cause mortality in a nationally representative sample of American adults.

Commercial viability depends on peer review and validation

The next figure that matters is not on this page: peer-review acceptance, clinical validation cohorts, or a licensing deal would each move the commercial calculus.

The last verified datapoint in the record is the preprint itself, filed August 25, 2026 under DOI 10.21203/rs.3.rs-10661096/v1 by Runliu Li, Shengnan He, Daniel Gruber and co-authors across the three institutions. Until review or replication arrives, the platform remains a laboratory result with a clear commercial thesis attached — not yet a product.

TriLink BioTechnologies, the supplier of the starting oligonucleotide library, was founded in 1996 and is headquartered in San Diego, where it maintains its manufacturing facilities.

Specializing in highly modified nucleic acids such as mRNA and custom oligonucleotides, the company was acquired by Maravai LifeSciences in 2016 and in 2019 moved into a 105,000 square-foot Maravai headquarters in Sorrento Valley, an investment of $40 million that added five manufacturing suites meeting the FDA’s Current Good Manufacturing Practices requirements. The same year, the City of San Diego proclaimed an “mRNA Day” in celebration of the new headquarters.

Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.

Photo of author

Newsroom

Newsroom at Archyde.

Social Security Raise Trimmed by Medicare Premium Hike